©2024 Stanford Medicine
A Study of Pemetrexed in Children With Recurrent Cancer
Not Recruiting
Trial ID: NCT00520936
Purpose
To determine the response rate of pemetrexed given every 21 days for the treatment of
children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive
neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma,
medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.
Official Title
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Patients must have osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma,
rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance 0,1,2
- Adequate renal, liver and bone marrow function
- Patient's current disease state must be one with no known curative therapy or therapy
proven to prolong survival with an acceptable quality of life
Exclusion Criteria:
- Growth factors that support platelet or white cell number or function must not have
been administered within the last 7 days prior to enrollment (14 days if Neulasta)
- Patients with central nervous system (CNS) tumors who have not been on a stable or
decreasing dose of dexamethasone or other corticosteroid for 7 days prior to
enrollment
- Patients with uncontrolled infection
- Patients who have received pemetrexed previously
- Patients with pleural effusions or ascites
Intervention(s):
drug: pemetrexed
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jennifer Lew
6507254318